Insmed Wins FDA Priority Review for ARIKAYCE sNDA
Bridgewater, New Jersey, U.S., September 21, 2026 Insmed has announced that the U.S. Food and Drug Administration (FDA) has...
respiratory disease
Advertisement
SMSbiotech Advances COPD Program With FDA IND Clearance
United States, September 17, 2026 SMSbiotech has announced that the U.S. Food and Drug Administration (FDA) has cleared its...
ENA Respiratory Advances INNA-051 Into Part B Phase IIa
MELBOURNE, Australia — September 15, 2026 ENA Respiratory announced that the first participants have been dosed in Part B...
Connect Biopharma Advances Rademikibart Toward Phase 3
SAN DIEGO, Calif. — September 15, 2026 Connect Biopharma Holdings Limited announced positive preliminary topline results from the global...
Sionna Advances SION-451 and SION-2222 Into Phase 2a
WALTHAM, Mass. — September 14, 2026 Sionna Therapeutics, Inc. announced plans to advance its preferred proprietary dual combination of...
Advertisements
Avalyn Pharma Presents New AP01 Data in Pulmonary Fibrosis
BOSTON — September 8, 2026 Avalyn Pharma presented new data at the European Respiratory Society (ERS) International Congress 2026...
Pulmovant Advances Mosliciguat Into Phase 3 After Positive PHocus Data
WALTHAM, Massachusetts — September 8, 2026 Pulmovant announced positive topline results from the Phase 2 PHocus study of mosliciguat...
Mabwell Reports 9MW1911 COPD Phase Ib/IIa Results
Shanghai, China, September 4, 2026 Mabwell (Shanghai) Bioscience Co., Ltd. has announced Phase Ib/IIa clinical results for its investigational...
Insmed Presents New ARIKAYCE Data From Phase 3b ENCORE
Bridgewater, New Jersey, USA, September 3, 2026 Insmed Incorporated announced that five abstracts from its respiratory portfolio have been...
United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
Advertisement
